

Special Issue

Therapy for HER2 Breast Cancer

Message from the Guest Editors

HER2, a HER family member, is a receptor tyrosine kinase expressed on the cell membrane, and constitutive activation of the protein via overexpression or gene aberrations such as amplification or single nucleotide variation transforms epithelial cells to cancer as demonstrated in preclinical models (ref.). HER2-driven breast cancer is an aggressive and distinct form of disease that occurs in young adults in advanced stages. Cancer with HER2 pathway activation spreads to the central nervous system easily and becomes resilient to systemic therapies. The advent of drug delivery systems such as antibody–drug conjugates (ADCs) further transformed the treatment of HER2-positive breast cancer, as shown in the pivotal trials of trastuzumab deruxtecan, and the disease has exhibited an increasingly more favorable prognosis with the ADC. This Special Issue will highlight the role of a new generation of HER2-targeting agents in their therapy, covering both basic and more (pre)clinical aspects that advance our understanding of targeting this pathway in breast cancer.

Guest Editors

Prof. Dr. Junji Tsurutani

Advanced Cancer Translational Research Institute, Showa University,
Tokyo 142-8555, Japan

Dr. Sandra M. Swain

Department of Medicine, Georgetown Lombardi Comprehensive
Cancer Center and MedStar Health, Washington, DC, USA

Deadline for manuscript submissions

31 August 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/242660

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)